![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
American Oil & Gas Common Stock | NYSE:AEZ | NYSE | Ordinary Share |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
Assay Allows Scientists to Identify Mutations and Copy Number Changes in a Single Reaction
Agilent Technologies Inc. (NYSE:A) today introduced OneSeq, the industry’s first all-in-one target enrichment product for next-generation sequencing. OneSeq is designed to detect and analyze copy number variations, loss of heterozygosity, and mutations in a single reaction for use in constitutional disease research.
Agilent is showcasing the new product at the annual Advances in Genome Biology and Technology (AGBT) conference in Marco Island, Florida, this week.
Powered by Agilent’s industry-leading SureSelect target-enrichment platform, the new OneSeq constitutional research panel will help laboratories involved in cytogenetic research save time gathering and analyzing complex, multifactorial data.
“OneSeq enables researchers to study both disease-associated targets and copy number variants at the same time,” said Alessandro Borsatti, a senior director of marketing at Agilent. “The all-in-one NGS assay—another industry first from the pioneers of target enrichment—provides more information than single molecular techniques, allowing scientists to streamline their workflow.”
Borsatti noted that researchers can easily combine OneSeq with Agilent’s free-of-charge SureCall software to integrate data analysis of copy number variations, single nucleotide polymorphisms, indels, and loss of heterozygosity.
“This combination offers the most cost-effective and streamlined method of studying multiple DNA changes associated with genetic disorders,” Borsatti said. “Whole genome sequencing and its associated data analysis are far more laborious and costly.”
In addition, Agilent’s online design application, SureDesign, enables researchers to customize OneSeq by adding any gene panel of interest to the CNV backbone to suit their needs.
About Agilent Technologies
Agilent Technologies Inc. (NYSE:A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. Agilent generated revenues of $4.0 billion in fiscal 2014. The company employs about 12,000 people worldwide. Information about Agilent is available at www.agilent.com.
NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.
for Agilent Technologies Inc.Jennifer Mann, +1 303-357-2391jmann@webershandwick.com
1 Year American Oil & Gas Common Stock Chart |
1 Month American Oil & Gas Common Stock Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions